Cryo-Cell International Inc Overview
Pro stress-test →Cryo-Cell International, Inc., founded in 1989, is the world's first private cord blood bank with more than 500,000 parents from 87 countries storing their baby's cord blood and cord tissue stem cells. The company operates both a private banking program and a public banking program in partnership with Duke University, with the public bank having provided cord blood for more than 600 transplantations.
Strategic Profile
Pro stress-test →Cryo-Cell reported a stockholders' deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years (fiscal 2023, 2024, and 2025). The company received acceptance of its compliance plan from NYSE American in May 2026, with a compliance period granted through September 9, 2027.
Competitive Landscape
Pro stress-test →Cryo-Cell operates in the cord blood banking and stem cell preservation market, competing with other private and public cord blood banks. The company differentiates through its first-mover status in private cord blood banking and clinical partnership with Duke University for public banking services. Competition includes other cord blood banking providers and emerging regenerative medicine storage companies.
Industry Context
Cryo-Cell International Inc operates in Cord Blood Banking and Stem Cell Preservation.
Key facts
Founded: 1989 · Headquarters: Oldsmar, US · Revenue: $7.9 million · Market cap: $36 million